Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.

摘要

A phase III trial investigated the efficacy of carboplatin and a taxane with and without cetuximab. a monoclonal antibody against EGFR, in patients with advanced non-small-cell lung cancer. This trial did not reveal an improvement in the primary end point of progression-free survival (according to an independent radiological review committee) with the addition of cetuximab to the carboplatin and taxane regimen. A retrospective investigation of potential biomarkers did not reveal any significant association between these biomarkers and cetuximab efficacy.